The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Of CAR s and TRUCK s: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma
Abstract
Summary: Adoptive T‐cell therapy recently achieved impressive efficacy in early phase trials, in particular in hematologic malignancies, strongly supporting the notion that the immune system can control cancer. A current strategy of favor is based on ex vivo‐engineered patient T cells, which are redirected by a chimeric antigen receptor (CAR) and recognize a predefined target by an antibody‐derived binding domain. Such CAR T cells can substantially reduce the tumor burden as long as the targeted antigen is present on the cancer cells. However, given the tremendous phenotypic diversity in solid tumor lesions, a reasonable number of cancer cells are not recognized by a given CAR, considerably reducing the therapeutic success. This article reviews a recently described strategy for overcoming this shortcoming of the CAR T‐cell therapy by modulating the tumor stroma by a CAR T‐cell‐secreted transgenic cytokine like interleukin‐12 (IL‐12). The basic process is that CAR T cells, when activated by their CAR, deposit IL‐12 in the targeted tumor lesion, which in turn attracts an innate immune cell response toward those cancer cells that are invisible to CAR T cells. Such TRUCK s, T cells redirected for universal cytokine‐mediated killing, exhibited remarkable efficacy against solid tumors with diverse cancer cell phenotypes, suggesting their evaluation in clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Interleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Development of T H 1 CD4 + T Cells Through IL-12 Produced by Listeria -Induced Macrophages
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O'Garra, A., & Murphy, K. M. (1993) · Science · doi:10.1126/science.8097338 · Cited by 3,134
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Rosenberg, S. A., Yang, J. C., Sherry, R. M., Kammula, U. S., Hughes, M. S., Phan, G. Q., Citrin, D. E., Restifo, N. P., Robbins, P. F., Wunderlich, J. R., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0116 · Cited by 2,140
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Cancer despite immunosurveillance: immunoselection and immunosubversion
Zitvogel, L., Tesniere, A., & Kroemer, G. (2006) · Nature reviews. Immunology · doi:10.1038/nri1936 · Cited by 1,324 · cited 1×
“These and other factors facilitate tumor relapse, despite high numbers of circulating tumor-specific T cells (10, 11).”
BackgroundRequirement for V α 14 NKT Cells in IL-12-Mediated Rejection of Tumors
Cui, J., Shin, T., Kawano, T., Sato, H., Kondo, E., Toura, I., Kaneko, Y., Koseki, H., Kanno, M., & Taniguchi, M. (1997) · Science · doi:10.1126/science.278.5343.1623 · Cited by 1,237
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050732 · Cited by 1,061
IL-23 promotes tumour incidence and growth
Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M. (2006) · Nature · doi:10.1038/nature04808 · Cited by 1,018
T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal
Kaliński, P., Hilkens, C. M. U., Wierenga, E. A., & Kapsenberg, M. L. (1999) · Immunology Today · doi:10.1016/s0167-5699(99)01547-9 · Cited by 933
The IL-12 Family of Heterodimeric Cytokines
Trinchieri, G., Pflanz, S., & Kastelein, R. A. (2003) · Immunity · doi:10.1016/s1074-7613(03)00296-6 · Cited by 922
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions
Hunter, C. A. (2005) · Nature Reviews Immunology · doi:10.1038/nri1648 · Cited by 852
Pegram, H. J., Lee, J. C., Hayman, E. G., Imperato, G. H., Tedder, T. F., Sadelain, M., & Brentjens, R. J. (2012) · Blood · doi:10.1182/blood-2011-12-400044 · Cited by 678
Munder, M., Mallo, M., Eichmann, K., & Modolell, M. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.12.2103 · Cited by 600
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Self-citationSignal 3 Determines Tolerance versus Full Activation of Naive CD8 T Cells
Curtsinger, J. M., Lins, D. C., & Mescher, M. F. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021910 · Cited by 509
Coughlin, C. M., Salhany, K. E., Wysocka, M., Aruga, E., Kurzawa, H., Chang, A. E., Hunter, C. A., Fox, J. C., Trinchieri, G., & Lee, W. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1555 · Cited by 415
Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice
Lu, T., Ramakrishnan, R., Altiok, S., Youn, J.-I., Cheng, P., Celis, E., Pisarev, V., Sherman, S., Sporn, M. B., & Gabrilovich, D. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45862 · Cited by 367
IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors
Kerkar, S. P., Goldszmid, R. S., Muranski, P., Chinnasamy, D., Yu, Z., Reger, R. N., Leonardi, A. J., Morgan, R. A., Wang, E., Marincola, F. M., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58814 · Cited by 342
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Chinnasamy, D., Yu, Z., Kerkar, S. P., Zhang, L., Morgan, R. A., Restifo, N. P., & Rosenberg, S. A. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-3050 · Cited by 277
Bystander elimination of antigen loss variants in established tumors
Spiotto, M. T., Rowley, D. A., & Schreiber, H. (2004) · Nature Medicine · doi:10.1038/nm999 · Cited by 260
Chmielewski, M., Hombach, A., Heuser, C., Adams, G. P., & Abken, H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.12.7647 · Cited by 260
Self-citationKerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Croci, D. O., Zacarías Fluck, M. F., Rico, M. J., Matar, P., Rabinovich, G. A., & Scharovsky, O. G. (2007) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-007-0343-y · Cited by 226
Eisenring, M., vom Berg, J., Kristiansen, G., Saller, E., & Becher, B. (2010) · Nature Immunology · doi:10.1038/ni.1947 · Cited by 221
The Toxicology of Interleukin-12: A Review
Car, B. D., Eng, V. M., Lipman, J. M., & Anderson, T. D. (1999) · Toxicologic Pathology · doi:10.1177/019262339902700112 · Cited by 220
Effects of IL-12 on the generation of cytotoxic activity in human CD8+ T lymphocytes.
Mehrotra, P. T., Wu, D., Crim, J. A., Mostowski, H. S., & Siegel, J. P. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2444 · Cited by 203
Terakura, S., Yamamoto, T. N., Gardner, R. A., Turtle, C. J., Jensen, M. C., & Riddell, S. R. (2012) · Blood · doi:10.1182/blood-2011-07-366419 · Cited by 196
Schurich, A., Pallett, L. J., Lubowiecki, M., Singh, H. D., Gill, U. S., Kennedy, P. T., Nastouli, E., Tanwar, S., Rosenberg, W., & Maini, M. K. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003208 · Cited by 186
Cavallo, F., Giovarelli, M., Forni, G., Signorelli, P., Musiani, P., Modesti, A., Brunda, M. J., & Colombo, M. P. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.14.1049 · Cited by 171
Sun, Y., Jurgovsky, K., Möller, P., Alijagic, S., Dorbic, T., Georgieva, J., Wittig, B., & Schadendorf, D. (1998) · Gene Therapy · doi:10.1038/sj.gt.3300619 · Cited by 164
Heinzerling, L., Burg, G., Dummer, R., Maier, T., Oberholzer, P. A., Schultz, J. G., Elzaouk, L., Pavlovic, J., & Moelling, K. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.35 · Cited by 154
Hombach, A. A., & Abken, H. (2011) · International Journal of Cancer · doi:10.1002/ijc.25960 · Cited by 152
Self-citationTatsumi, T., Huang, J., Gooding, W. E., Gambotto, A. A., Robbins, P. D., Vujanović, N. L., Alber, S. M., Watkins, S. C., Okada, H., & Storkus, W. J. (2003) · PubMed · Cited by 140
Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S., Lee, M. H., Park, K., Kım, K., Jeong, H. S., Kim, J., et al. (2001) · Human Gene Therapy · doi:10.1089/104303401300057388 · Cited by 132
Yoo, J. K., Cho, J., Lee, S. W., & Sung, Y. C. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.7.3637 · Cited by 128
The T-Body Approach: Redirecting T Cells with Antibody Specificity
Eshhar, Z. (2007) · Handbook of experimental pharmacology · doi:10.1007/978-3-540-73259-4_14 · Cited by 111
van Herpen, C. M. L., van der Laak, J. A. W. M., de Vries, I. J. M., van Krieken, J. H., de Wilde, P. C., Balvers, M. G. J., Adema, G. J., & Mulder, P. H. M. D. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-1524 · Cited by 104
Mortarini, R., Borri, A., Tragni, G., Bersani, I., Vegetti, C., Bajetta, E., Pilotti, S., Cerundolo, V., & Anichini, A. (2000) · PubMed · Cited by 98
Wesa, A. K., Kaliński, P., Kirkwood, J. M., Tatsumi, T., & Storkus, W. J. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211316.15278.6e · Cited by 87
Wagner, H., Bollard, C. M., Vigouroux, S., Huls, M. H., Anderson, R. W., Prentice, H. G., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2003) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700664 · Cited by 80
Simpson-Abelson, M. R., Purohit, V. S., Pang, W. M., Iyer, V., Odunsi, K. O., Demmy, T. L., Yokota, S. J., Loyall, J. L., Kelleher, R. J., Balu‐Iyer, S. V., et al. (2009) · Clinical Immunology · doi:10.1016/j.clim.2009.03.516 · Cited by 51
Durrant, D. M., & Metzger, D. W. (2010) · Mucosal Immunology · doi:10.1038/mi.2010.9 · Cited by 38
Ju, D., Yang, Y., Tao, Q., Song, W., He, L., Chen, G., Gu, S., Ting, C. C., & Cao, X. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301291 · Cited by 38
Dowell, A. C., Oldham, K. A., Bhatt, R. I., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1122-3 · Cited by 36
Curti, A., Parenza, M., & Colombo, M. P. (2002) · Blood · doi:10.1182/blood-2002-03-0991 · Cited by 22
Fan, H., Walters, C. S., Dunston, G. M., & Tackey, R. (2002) · Cytokine · doi:10.1006/cyto.2002.1958 · Cited by 20
Wagner, H.-J., Sili, U., Gahn, B., Vigouroux, S., Huls, M. H., Xie, W., Vignali, D. A. A., Brenner, M. K., Heslop, H., & Rooney, C. M. (2003) · Cytotherapy · doi:10.1080/14653240310001262 · Cited by 19
Díaz-Montero, C. M., Naga, O. S., Zidan, A. A., Salem, M., Pallin, M., Parmigiani, A., Walker, G. R., Wieder, E., Komanduri, K. V., Cole, D. J., et al. (2011) · Europe PMC (PubMed Central) · Cited by 18
Förster, A., Falcone, F. H., Gibbs, B. F., Preußner, L., Fiebig, B. S., Altunok, H., Seeger, J. M., Cerny‐Reiterer, S., Rabenhorst, A., Papenfuss, K., et al. (2012) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2012.731600 · Cited by 13
The Anti-Tumor Effect of Interleukin-12 is Enhanced by Mild (Fever-Range) Thermal Therapy
Pritchard, M. T., Wolf, S. F., Kraybill, W., & Repasky, E. A. (2005) · Immunological Investigations · doi:10.1081/imm-200067646 · Cited by 13
Cited by
CAR-T cell therapy: current limitations and potential strategies
Sterner, R. C., & Sterner, R. M. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00459-7 · Cited by 2,926
Engineering strategies to overcome the current roadblocks in CAR T cell therapy
Rafiq, S., Hackett, C. S., & Brentjens, R. J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0297-y · Cited by 1,472
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,296
CAR T Cell Therapy for Solid Tumors
Newick, K., O'Brien, S., Moon, E., & Albelda, S. M. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-062315-120245 · Cited by 909
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Metadata
- Authors
- Chmielewski, M., Hombach, A. A., & Abken, H.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2013-12-13
- Volume
- 257
- Issue
- 1
- Pages
- 83-90
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2068173904
- Cited by
- 356
- References
- 58
- FWCI
- 1.43
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.